Compare Quest Diagnostics Inc (DGX) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Okta, Inc. — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Okta, Inc. trades at $232.13 (market cap $38.50B). The key difference: Okta, Inc. is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Okta, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Okta, Inc. for 44 Days on average.
| DGX | OKTA | |
|---|---|---|
Market Cap | $25.48B | $38.50B |
Volume | 941,866 | 2,479,621 |
Sector | Health | Technology |
52-Week High | $247.45 | $232.13 |
52-Week Low | $173.49 | $62.93 |
Typical Hold Time | 56 Days | 44 Days |
Enterprise Value | $31.23B | $36.25B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% with strong year-to-date performance driven by organic growth and advanced diagnostics adoption. The company has consistently beaten earnings expectations in recent quarters with Q2 2026 EPS of $3.12 exceeding estimates. Technical indicators show a bearish bias while fundamentals remain solid with 9.19% net margin and 14.35% ROE. Recent developments include a partnership with Apple Health app and positive clinical study results.
DGX presents a mixed outlook with strong fundamental performance offset by technical weakness and regulatory headwinds. The 38% upside to consensus price target of $250 offers potential, but Medicare reimbursement cuts and bearish technical signals warrant caution. Growth in consumer testing and strategic partnerships provide catalysts, though execution risks and debt levels require monitoring.
Okta (OKTA) trades at $220.21, up 1.01% on the day, with a bullish technical signal from moving averages. The stock has consistently beaten earnings estimates in recent quarters. Revenue growth is strong, reaching $2.61B in 2025, with the company achieving positive net income for the first time. Recent news highlights its strategic focus on AI agent security, with announcements at the Oktane 2026 conference generating positive analyst attention.
The outlook is positive, driven by strong fundamentals and Wall Street's bullish consensus, though high valuation multiples and recent insider selling present risks. The key opportunity lies in Okta's positioning in the growing AI security market, while execution against competition remains a challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
